Oliver Wisser¹, Bastian Gutmann¹, Adam Seymour^2
1VITROCELL Systems GmbH 79183 Waldkirch, Germany
²Covance Laboratories Ltd Harrogate, UK

The poster shows the new media inserts.

Read more

Following the VITROCELL® User Group Meeting 2018 in San Antonio, Texas, USA, international scientists from Europe, Japan, Korea and USA reconvened in March 2019.

The informal event organized into short presentations and posters was followed by open discussions. It was an excellent opportunity to discuss the latest developments of VITROCELL®, to exchange your experience in working with the equipment and to meet other fellow researchers.
The meeting took place prior to the international Society of Toxicology 58th Annual Meeting and ToxExpo, March 10 – 14, 2018, in Baltimore, USA - one of the largest international conferences related to toxicology.

Focus of the event was to share VITROCELL® activities since the last meeting, to exchange latest research results, to give an update on VITROCELL’s participation in major research programs as well as the presentation of new products for 2019.

Read more

https://doi.org/10.1016/j.yrtph.2018.05.004

Shinkichi Ishikawa∗, Kazushi Matsumura, Nobumasa Kitamura, Kanae Ishimori, Yuichiro Takanami, Shigeaki Ito

The experimental setup for the aerosol exposure consisted of a VC 10 smoking robot, a dilution system, and a Vitrocell 12/3 glass module the exposure of nicotine and TPM in the mainstream aerosols from 3R4F and novel tobacco vapor on MucilAir™ cells. The results are shown in cytotoxicity, IL-8, IL-1ß and gene expression.

Read more

DOI: 10.1089/aivt.2018.0001
Holger Behrsing,¹ Mario Aragon,¹ Jason Adamson,² Devin Sheehan,¹ Marianna Gaca,² Rodger Curren,¹ and Erin Hill^1
1Respiratory Toxicology, Institute for In Vitro Sciences, Inc., Gaithersburg, Maryland.
²R&D, British American Tobacco, Southampton, United Kingdom.

The study shows an assessment of VC1 aerosol generation that was conducted by measuring puff-by-puff in vitro nicotine concentration of 3R4F cigarettes (ISO and HCI regimes), e-cigarette (CRM81 puffing profile), and THP (HCIm regime). The aerosols were applied to in vitro or ex vivo cellular and tissue systems that model the respiratory tract, such as reconstructed human airways (RHuA), which are grown at the air–liquid interface (ALI). Additionally a comparison between the Vitrocell VC1 (U.S. Laboratory) and the VC10 (UK Laboratory) Smoking Robot was done.

Read more

D. Sheehan¹, M. Aragon¹, J. Adamson², M. Gaca², H. Raabe¹, and H. Behrsing¹.
¹Institute for In Vitro Sciences, Inc., Gaithersburg, MD; and 2British American Tobacco, Southampton, United Kingdom.

This study demonstrates successful Vitrocell VC1 aerosol generation and delivery across multiple nicotine product categories (3R4F cigarette smoke, e-liquid and THP), as characterised using nicotine as a dosimetry marker. The data suggests the VC1 can reproducibly generate and deliver tobacco product and NGP aerosols for future in vitro assessment and matches the performance of reported exposure systems.

Read more